|
US4166452A
(en)
|
1976-05-03 |
1979-09-04 |
Generales Constantine D J Jr |
Apparatus for testing human responses to stimuli
|
|
US4256108A
(en)
|
1977-04-07 |
1981-03-17 |
Alza Corporation |
Microporous-semipermeable laminated osmotic system
|
|
US4265874A
(en)
|
1980-04-25 |
1981-05-05 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
|
LU86084A1
(fr)
|
1985-09-20 |
1987-04-02 |
Faco Sa |
Apparei de massage electrique
|
|
US5102417A
(en)
|
1985-11-07 |
1992-04-07 |
Expandable Grafts Partnership |
Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
|
|
US4800882A
(en)
|
1987-03-13 |
1989-01-31 |
Cook Incorporated |
Endovascular stent and delivery system
|
|
US4886062A
(en)
|
1987-10-19 |
1989-12-12 |
Medtronic, Inc. |
Intravascular radially expandable stent and method of implant
|
|
WO1990013332A1
(en)
|
1989-05-11 |
1990-11-15 |
Cedars-Sinai Medical Center |
Stent with sustained drug delivery
|
|
WO1991012779A1
(en)
|
1990-02-28 |
1991-09-05 |
Medtronic, Inc. |
Intralumenal drug eluting prosthesis
|
|
US5419760A
(en)
|
1993-01-08 |
1995-05-30 |
Pdt Systems, Inc. |
Medicament dispensing stent for prevention of restenosis of a blood vessel
|
|
US5429634A
(en)
|
1993-09-09 |
1995-07-04 |
Pdt Systems |
Biogenic implant for drug delivery and method
|
|
US6774278B1
(en)
|
1995-06-07 |
2004-08-10 |
Cook Incorporated |
Coated implantable medical device
|
|
DE19539091A1
(de)
|
1995-10-20 |
1997-04-24 |
Thomae Gmbh Dr K |
5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zur ihrer Herstellung
|
|
JPH11513382A
(ja)
|
1995-10-20 |
1999-11-16 |
ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
|
|
US5833651A
(en)
|
1996-11-08 |
1998-11-10 |
Medtronic, Inc. |
Therapeutic intraluminal stents
|
|
US6294192B1
(en)
|
1999-02-26 |
2001-09-25 |
Lipocine, Inc. |
Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
|
|
PY0117895A
(es)
|
2000-07-31 |
2003-11-03 |
Pfizer Prod Inc |
Derivados de imidazol
|
|
US6756385B2
(en)
|
2000-07-31 |
2004-06-29 |
Pfizer Inc. |
Imidazole derivatives
|
|
KR20030030029A
(ko)
|
2000-09-22 |
2003-04-16 |
니혼노야쿠가부시키가이샤 |
Ｎ-(4-피라졸릴)아미드 유도체 및 농원예용 약제 그리고그 사용방법
|
|
US7589199B2
(en)
*
|
2002-06-12 |
2009-09-15 |
Chemocentryx, Inc. |
Substituted piperazines
|
|
US20050256130A1
(en)
|
2002-06-12 |
2005-11-17 |
Chemocentryx, Inc. |
Substituted piperazines
|
|
US7842693B2
(en)
|
2002-06-12 |
2010-11-30 |
Chemocentryx, Inc. |
Substituted piperazines
|
|
US6770729B2
(en)
|
2002-09-30 |
2004-08-03 |
Medtronic Minimed, Inc. |
Polymer compositions containing bioactive agents and methods for their use
|
|
AU2004236240C1
(en)
|
2003-05-01 |
2010-11-04 |
Bristol-Myers Squibb Company |
Aryl-substituted pyrazole compounds useful as kinase inhibitors
|
|
US7381714B2
(en)
|
2005-05-19 |
2008-06-03 |
Cv Therapeutics, Inc. |
A1 adenosine receptor agonists
|
|
MX2007015917A
(es)
*
|
2005-06-22 |
2008-03-10 |
Chemocentryx Inc |
Compuestos de azaindazol y metodos de uso.
|
|
US7777035B2
(en)
*
|
2005-06-22 |
2010-08-17 |
Chemocentryx, Inc. |
Azaindazole compounds and methods of use
|
|
FR2887450B1
(fr)
|
2005-06-23 |
2007-08-24 |
Rhodia Chimie Sa |
Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques
|
|
JPWO2007026834A1
(ja)
*
|
2005-09-01 |
2009-03-12 |
クミアイ化学工業株式会社 |
ピラゾール誘導体及び農園芸用除草剤
|
|
WO2007073432A2
(en)
*
|
2005-10-11 |
2007-06-28 |
Chemocentryx, Inc. |
Piperidine derivatives and methods of use
|
|
US20090252779A1
(en)
|
2006-06-22 |
2009-10-08 |
Chemocentryx, Inc. |
Azaindazole compounds and methods of use
|
|
EP2079728B1
(en)
|
2006-10-10 |
2013-09-25 |
Amgen Inc. |
N-aryl pyrazole compounds for use against diabetes
|
|
US20100113776A1
(en)
*
|
2006-12-14 |
2010-05-06 |
Taisho Pharmaceutical Co.,Ltd. |
Pyrazole derivative
|
|
US7786157B2
(en)
|
2007-03-16 |
2010-08-31 |
Chemocentryx, Inc. |
OXO-imidazolidines as modulators of chemokine receptors
|
|
EA015529B1
(ru)
|
2007-05-22 |
2011-08-30 |
Кемосентрикс, Инк. |
3-(имидазолил)пиразоло[3,4-b]пиридины
|
|
JP5191537B2
(ja)
|
2007-06-18 |
2013-05-08 |
エム・エス・ディー・オス・ベー・フェー |
ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
|
|
SI3184527T1
(sl)
|
2007-06-22 |
2020-03-31 |
Eli Lilly And Company |
Spojine 2,6-diokso,-2,3-dihidro-1H-purina uporabne za zdravljenje stanj povezanih z aktivnostjo TRPA1 kanala
|
|
EP2221298B1
(en)
|
2007-11-13 |
2013-11-06 |
Taisho Pharmaceutical Co., Ltd |
Phenylpyrazole derivatives
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
US8293917B2
(en)
|
2008-05-06 |
2012-10-23 |
Boehringer Ingelheim International Gmbh |
Pyrazole compounds as CCR1 antagonists
|
|
US20120108614A1
(en)
|
2008-05-14 |
2012-05-03 |
Chong Jayhong A |
Compounds and compositions for treating chemical warfare agent-induced injuries
|
|
DK2323663T3
(en)
*
|
2008-09-11 |
2015-06-01 |
Chemocentryx Inc |
4-amino-3- (imidazolyl) pyrazolo [3,4-d] pyrimidines
|
|
BRPI0919377A2
(pt)
|
2008-09-26 |
2016-09-27 |
Dana Farber Cancer Inst Inc |
anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
|
|
WO2010053861A2
(en)
|
2008-11-07 |
2010-05-14 |
H. Lundbeck A/S |
Biologically active amides
|
|
ES2629337T3
(es)
|
2009-02-09 |
2017-08-08 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
|
|
GB0915892D0
(en)
|
2009-09-10 |
2009-10-14 |
Smithkline Beecham Corp |
Compounds
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
CN103732238A
(zh)
|
2011-06-08 |
2014-04-16 |
奥瑞基尼探索技术有限公司 |
用于免疫调节的治疗性化合物
|
|
KR101981873B1
(ko)
|
2011-11-28 |
2019-05-23 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
CN104159911A
(zh)
|
2012-03-07 |
2014-11-19 |
奥瑞基尼探索技术有限公司 |
作为免疫调节剂的模拟肽化合物
|
|
CN104245726A
(zh)
|
2012-03-29 |
2014-12-24 |
奥瑞基尼探索技术有限公司 |
来自人pd1的bc环的免疫调节环状化合物
|
|
US9212224B2
(en)
|
2012-05-15 |
2015-12-15 |
Bristol-Myers Squibb Company |
Antibodies that bind PD-L1 and uses thereof
|
|
RU2689760C2
(ru)
|
2012-05-31 |
2019-05-30 |
Дженентек, Инк. |
Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
WO2014089498A1
(en)
|
2012-12-07 |
2014-06-12 |
Optionality Holdings, Inc. |
Compliance service
|
|
EP2928474B1
(en)
|
2012-12-07 |
2018-11-14 |
ChemoCentryx, Inc. |
Diazole lactams
|
|
MX2015007853A
(es)
|
2012-12-21 |
2015-09-29 |
Chemocentryx Inc |
Diazol amidas.
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
AU2014290069B2
(en)
|
2013-07-16 |
2019-01-03 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
|
|
JP6586087B2
(ja)
|
2013-08-20 |
2019-10-02 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療
|
|
EA029901B1
(ru)
|
2013-09-04 |
2018-05-31 |
Бристол-Майерс Сквибб Компани |
Соединения для применения в качестве иммуномодуляторов
|
|
HRP20181251T1
(hr)
|
2013-09-06 |
2018-10-05 |
Aurigene Discovery Technologies Limited |
Derivati 1,3,4-oksadiazola i 1,3,4-tiadiazola kao imunomodulatori
|
|
CU24362B1
(es)
|
2013-09-06 |
2018-10-04 |
Aurigene Discovery Tech Ltd |
Derivados de 1,2,4-oxadiazol como inmunomoduladores
|
|
AU2014316686B2
(en)
|
2013-09-06 |
2018-11-22 |
Aurigene Discovery Technologies Limited |
Cyclic peptidomimetic compounds as immunomodulators
|
|
WO2015036927A1
(en)
|
2013-09-10 |
2015-03-19 |
Aurigene Discovery Technologies Limited |
Immunomodulating peptidomimetic derivatives
|
|
WO2015044900A1
(en)
|
2013-09-27 |
2015-04-02 |
Aurigene Discovery Technologies Limited |
Therapeutic immunomodulating compounds
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
EP3904388A1
(en)
|
2014-05-27 |
2021-11-03 |
Academia Sinica |
Fucosidase from bacteroides and methods using the same
|
|
CA2960778C
(en)
|
2014-09-11 |
2023-03-07 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions
|
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
BR112017019307A2
(pt)
|
2015-03-10 |
2018-05-02 |
Aurigene Discovery Technologies Limited |
compostos de 1,3,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
|
|
WO2016142886A2
(en)
|
2015-03-10 |
2016-09-15 |
Aurigene Discovery Technologies Limited |
3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
|
MX384444B
(es)
|
2015-03-10 |
2025-03-14 |
Aurigene Discovery Tech Ltd |
Compuestos de 1,2,4-oxadiazol y tiadiazol como inmunomoduladores
|
|
SG11201706901TA
(en)
|
2015-03-10 |
2017-09-28 |
Aurigene Discovery Tech Ltd |
Therapeutic cyclic compounds as immunomodulators
|
|
CA2979145A1
(en)
|
2015-03-10 |
2016-09-15 |
Aurigene Discovery Technologies Limited |
1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
|
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
TWI808938B
(zh)
|
2016-04-07 |
2023-07-21 |
美商卡默森屈有限公司 |
藉由投予ccr1拮抗劑與pd-1抑制劑或pd-l1抑制劑之組合減少腫瘤負荷
|